BeiGene reports H1 2023 R&D expenses of $831M; breakdown by key pipeline assets

BeOne Medicines Ltd.

Total R&D expenses for H1 2023 were $831.3M, up from $768.1M in H1 2022.
Zanubrutinib R&D: $81.1M (H1 2023) vs $71.0M (H1 2022).
Tislelizumab R&D: $47.0M; Ociperlimab: $38.8M; Pamiparib: $4.4M.
Bcl-2 (BGB-11417) R&D: $17.5M; OX40 (BGB-A445): $8.9M; other projects: $60.6M.
Differences between PRC GAAP and US GAAP summarized, mainly share-based comp and leasing treatment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.